Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study
Crossref DOI link: https://doi.org/10.1007/s12032-015-0686-8
Published Online: 2015-09-07
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Xiaohui
Zhou, Yidong
Mao, Feng
Lin, Yan
Guan, Jinghong
Sun, Qiang
Text and Data Mining valid from 2015-09-07